Baseline characteristics and patient disposition
| Characteristic . | Prior line of therapy . | Total (N = 63) . | ||
|---|---|---|---|---|
| RTX (n = 17) . | RTX-CIT (n = 40) . | Other* (n = 6) . | ||
| Median age (range), y | 66.0 (30-86) | 64.5 (41-90) | 82.0 (57-92) | 66.0 (30-92) |
| Age ≥65 y, n (%) | 11 (65) | 20 (50) | 5 (83) | 36 (57) |
| Bulky disease status, n (%) | ||||
| Not bulky (≤6 cm) | 12 (71) | 27 (68) | 4 (67) | 43 (68) |
| Bulky (>6 cm) | 3 (18) | 10 (25) | 1 (17) | 14 (22) |
| NA, spleen only | 2 (12) | 3 (8) | 1 (17) | 6 (10) |
| Bone marrow involvement, n (%) | 8 (47) | 13 (33) | 0 | 21 (33) |
| Baseline cytopenias, n (%) | ||||
| Any cytopenia | 10 (59) | 15 (38) | 2 (33) | 27 (43) |
| Hemoglobin ≤11 g/dL | 10 (59) | 15 (38) | 2 (33) | 27 (43) |
| Platelets ≤100 × 109/L | 1 (6) | 5 (13) | 0 | 6 (10) |
| ANC ≤1.5 × 109/L | 1 (6) | 0 | 0 | 1 (2) |
| LDH ≥350 U/L, n (%) | 1 (6) | 10 (25) | 1 (17) | 12 (19) |
| Creatinine clearance <60 mL/min, n (%) | 1 (6) | 4 (10) | 4 (67) | 9 (14) |
| Median number of prior systemic therapies (range) | 1.0 (1-4) | 2.0 (1-9) | 2.5 (2-5) | 2.0 (1-9) |
| 1, n (%) | 14 (82) | 9 (23) | 0 | 23 (37) |
| 2, n (%) | 2 (12) | 13 (33) | 3 (50) | 18 (29) |
| ≥3, n (%) | 1 (6) | 18 (45) | 3 (50) | 22 (35) |
| Patients refractory† to their last prior therapy at enrollment, n (%) | 8 (57) | 4 (10) | 2 (33) | 14 (22) |
| Distribution of MZL subtype, n (%)‡ | ||||
| Extranodal | 9 (53) | 21 (53) | 2 (33) | 32 (51) |
| Nodal | 1 (6) | 13 (33) | 3 (50) | 17 (27) |
| Splenic | 7 (41) | 6 (15) | 1 (17) | 14 (22) |
| Characteristic . | Prior line of therapy . | Total (N = 63) . | ||
|---|---|---|---|---|
| RTX (n = 17) . | RTX-CIT (n = 40) . | Other* (n = 6) . | ||
| Median age (range), y | 66.0 (30-86) | 64.5 (41-90) | 82.0 (57-92) | 66.0 (30-92) |
| Age ≥65 y, n (%) | 11 (65) | 20 (50) | 5 (83) | 36 (57) |
| Bulky disease status, n (%) | ||||
| Not bulky (≤6 cm) | 12 (71) | 27 (68) | 4 (67) | 43 (68) |
| Bulky (>6 cm) | 3 (18) | 10 (25) | 1 (17) | 14 (22) |
| NA, spleen only | 2 (12) | 3 (8) | 1 (17) | 6 (10) |
| Bone marrow involvement, n (%) | 8 (47) | 13 (33) | 0 | 21 (33) |
| Baseline cytopenias, n (%) | ||||
| Any cytopenia | 10 (59) | 15 (38) | 2 (33) | 27 (43) |
| Hemoglobin ≤11 g/dL | 10 (59) | 15 (38) | 2 (33) | 27 (43) |
| Platelets ≤100 × 109/L | 1 (6) | 5 (13) | 0 | 6 (10) |
| ANC ≤1.5 × 109/L | 1 (6) | 0 | 0 | 1 (2) |
| LDH ≥350 U/L, n (%) | 1 (6) | 10 (25) | 1 (17) | 12 (19) |
| Creatinine clearance <60 mL/min, n (%) | 1 (6) | 4 (10) | 4 (67) | 9 (14) |
| Median number of prior systemic therapies (range) | 1.0 (1-4) | 2.0 (1-9) | 2.5 (2-5) | 2.0 (1-9) |
| 1, n (%) | 14 (82) | 9 (23) | 0 | 23 (37) |
| 2, n (%) | 2 (12) | 13 (33) | 3 (50) | 18 (29) |
| ≥3, n (%) | 1 (6) | 18 (45) | 3 (50) | 22 (35) |
| Patients refractory† to their last prior therapy at enrollment, n (%) | 8 (57) | 4 (10) | 2 (33) | 14 (22) |
| Distribution of MZL subtype, n (%)‡ | ||||
| Extranodal | 9 (53) | 21 (53) | 2 (33) | 32 (51) |
| Nodal | 1 (6) | 13 (33) | 3 (50) | 17 (27) |
| Splenic | 7 (41) | 6 (15) | 1 (17) | 14 (22) |
ANC, absolute neutrophil count; LDH, lactate dehydrogenase; NA, not applicable.
Patients in the “Other” category had prior treatment with both single-agent RTX and chemotherapy or investigational therapies.
Defined as documented failure to achieve at least PR.
Percentages may not total 100 because of rounding.